Compare ResMed Inc. (RMD) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? ResMed Inc. trades at $223.62 (market cap $31.92B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: ResMed Inc. pays a 1.2% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and ResMed Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| RMD | VCIT | |
|---|---|---|
Market Cap | $31.92B | — |
Sector | Health | Fixed Income |
52-Week High | $293.73 | $84.82 |
52-Week Low | $182.82 | $81.07 |
Enterprise Value | $31.28B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.42, up 0.17% over 24 hours. The technical outlook is neutral with bearish moving averages, while recent news highlights its low 0.03% expense ratio and competitive yield. Dividend distributions are scheduled through mid-2026, providing steady income.
The ETF offers a balance of yield and moderate risk through investment-grade corporate bonds. Key risks include interest rate sensitivity and economic volatility. Analyst sentiment is mixed, emphasizing cost efficiency but cautioning on duration exposure in a shifting rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
